Drug intelligence / Profile preview

CTRP9

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes
Administration: Systemic, Intravenous, Subcutaneous

Overview

CTRP9 is a novel adipokine closely related to adiponectin. It plays a significant role in regulating glucose and lipid metabolism, vasodilation, and cell differentiation by activating various signaling pathways. It has been implicated in protecting against atherosclerosis and improving outcomes in cardiovascular diseases like diabetic heart injury and atrial fibrillation. CTRP9 also shows potential as a biomarker for ischemic stroke.

Other names: C1q/TNF-related protein 9

Targets

AdipoR (Adiponectin receptor)CDH2 (N-cadherin)ADIPOR1 (Adiponectin receptor 1)

Beyond the preview

Go deeper on CTRP9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTRP9.

Explore the full profile